ClinicalTrials.gov
ClinicalTrials.gov Menu

Study on Management Thrombosis in Greek Cancer Patients (GMaT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03292107
Recruitment Status : Recruiting
First Posted : September 25, 2017
Last Update Posted : September 25, 2017
Sponsor:
Information provided by (Responsible Party):
Hellenic Society of Medical Oncology

Brief Summary:
Study on Management Thrombosis in Greek cancer patients

Condition or disease
Thrombosis

Detailed Description:
The approach that Medical Oncologists encounter the prospect of a coagulation event occurrence in cancer patients.

Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study on Management Thrombosis in Greek Cancer Patients (GMaT - Greek Management Thrombosis)
Actual Study Start Date : June 1, 2016
Estimated Primary Completion Date : October 31, 2017
Estimated Study Completion Date : February 28, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Clots




Primary Outcome Measures :
  1. The clinical practice for patients under anticoagulation regime [ Time Frame: 1 YEAR ]
    Documentation of the clinical practice for patients under anticoagulation regime, for prophylaxis or treatment, in patients with solid tumors, for one year following the protocol initiation date, including high-risk patients as defined in the protocol.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with solid tumors under anticoagulation regime, for prophylaxis or treatment.
Criteria

Inclusion Criteria

  • All patients diagnosed with histologically confirmed solid tumors that are under anticoagulation therapy, during the study timeline.
  • Age ≥ 18 years
  • Signed informed consent

Exclusion Criteria

  • Initiation of anticoagulation therapy before the initiation of the study in 2016
  • Age <18 years
  • No signed informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03292107


Contacts
Contact: Nikolaos Tsoukalas, MD +30 2107288598 tsoukn@yahoo.gr

Locations
Greece
Hellenic Society of Medical Oncology Recruiting
Athens, Greece, 11475
Contact: Kalliopi Sarikaki, SC    +302106457971    psarikaki@hesmo.gr   
Sponsors and Collaborators
Hellenic Society of Medical Oncology
Investigators
Principal Investigator: Ioannis Varthalitis, MD Hellenic Society of Medical Oncology

Responsible Party: Hellenic Society of Medical Oncology
ClinicalTrials.gov Identifier: NCT03292107     History of Changes
Other Study ID Numbers: Management Thrombosis
First Posted: September 25, 2017    Key Record Dates
Last Update Posted: September 25, 2017
Last Verified: July 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases